K K Van de Vijver
Overview
Explore the profile of K K Van de Vijver including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Baal J, Lok C, Jordanova E, Horlings H, van Driel W, Amant F, et al.
Virchows Arch
. 2020 Dec;
478(3):611.
PMID: 33263796
No abstract available.
2.
van Baal J, Lok C, Jordanova E, Horlings H, van Driel W, Amant F, et al.
Virchows Arch
. 2020 Mar;
477(4):535-544.
PMID: 32179982
Peritoneal metastases of high-grade serous ovarian cancer (HGSOC) are small-sized deposits with superficial growth toward the peritoneal cavity. It is unknown whether integrity of the peritoneal elastic lamina (PEL) correlates...
3.
Timmermans M, Zwakman N, Sonke G, Van de Vijver K, Duk M, van der Aa M, et al.
Eur J Obstet Gynecol Reprod Biol
. 2019 Aug;
240:364-369.
PMID: 31400565
Objective: Despite being the most important prognostic factor for prolonged overall survival in epithelial ovarian cancer (EOC), the measurement of residual disease is hampered by its subjective character. Additional assessment...
4.
van der Hel O, Timmermans M, van Altena A, Kruitwagen R, Slangen B, Sonke G, et al.
Eur J Cancer
. 2019 Jul;
118:97-104.
PMID: 31326731
Introduction: About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs) and sarcomas. Because these non-epithelial ovarian tumours are rare and population-based...
5.
Koole S, Kieffer J, Sikorska K, Schagen van Leeuwen J, Schreuder H, Hermans R, et al.
Eur J Surg Oncol
. 2019 May;
47(1):101-107.
PMID: 31128948
Introduction: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improves recurrence-free (RFS) and overall survival (OS) in patients with FIGO stage III ovarian cancer. We evaluated...
6.
Timmermans M, Sonke G, Slangen B, Baalbergen A, Bekkers R, Fons G, et al.
Eur J Surg Oncol
. 2019 Apr;
45(8):1425-1431.
PMID: 31027945
Introduction: The care for patients with epithelial ovarian cancer(EOC) is organised in eight different geographical regions in the Netherlands. This situation allows us to study differences in practice patterns and...
7.
van Baal J, Van de Vijver K, Algera M, van der Aa M, Sonke G, van Driel W, et al.
Gynecol Oncol
. 2019 Apr;
153(3):562-567.
PMID: 30948193
Objective: The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy...
8.
Timmermans M, van der Hel O, Sonke G, Van de Vijver K, van der Aa M, Kruitwagen R
Gynecol Oncol
. 2019 Mar;
153(2):445-451.
PMID: 30826010
Introduction: The ability to minimize residual disease during primary cytoreductive surgery is the strongest predictor for improved overall survival in advanced ovarian cancer. But while the probability to achieve a...
9.
Timmermans M, Sonke G, Van de Vijver K, Ottevanger P, Nijman H, van der Aa M, et al.
Int J Gynecol Cancer
. 2019 Jan;
29(2):392-397.
PMID: 30665898
Background: Patients with ovarian cancer who are diagnosed with Federation of Gynecology and Obstetrics (FIGO) stage IV disease are a highly heterogeneous group with possible survival differences. The FIGO staging...
10.
Timmermans M, van der Aa M, Lalisang R, Witteveen P, Van de Vijver K, Kruitwagen R, et al.
Gynecol Oncol
. 2018 Jul;
150(3):446-450.
PMID: 30001834
Objective: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to...